BioIntelliSense has upgraded its Data-as-a-Service health monitoring platform to better track the symptoms of sick patients. The improved system will utilize the company’s on-body BioSticker to measure the frequency of symptoms like coughing, sneezing, or even vomiting on a minute-by-minute basis.
“Objective measurement of a patient’s symptomatic events, in addition to vital signs of skin temperature, respiratory rate and heart rate, enable opportunities for earlier, proactive clinical intervention,” said BioIntelliSense CEO James Mault.
The BioSticker is a single-use device that remotely monitors a patient’s physiological vital signs. It can be deployed alongside BioIntelliSense’s new BioHub, a 5G device that consolidates medical data and automatically uploads it to the cloud. The data then be analyzed to make a more accurate diagnosis and provide more responsive care. The FDA cleared the BioSticker for commercial launch back in January.
BioIntelliSense notes that its suite of Remote Patient Monitoring products and services can be utilized in a wide variety of clinical settings. For example, the BioSticker can now monitor many of the primary symptoms associated with the COVID-19 coronavirus, which could help healthcare professionals track the progress of the infection.
BioIntelliSense is not the only healthcare provider highlighting potential applications of the technology in the current health environment. ViTel Net emphasized the utility of its vCareCommand and Remote Patient Monitoring solutions in response to the recent outbreak.
March 10, 2020 – by Eric Weiss